Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1476-1485

  Xu, Hui ^a   Yang, Yue Jin ^a   Qian, Hai Yan ^a   Tang, Yi Da ^a   Wang, Hong ^a   Zhang, Qian ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

JAK STAT; Mesenchymal stem cells; Myocardial infarction; Rosuvastatin

Indexed keywords

JANUS KINASE; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; ROSUVASTATIN; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; INTERMETHOD COMPARISON; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MUSCLE DEVELOPMENT; NONHUMAN; RAT; SIGNAL TRANSDUCTION; Y CHROMOSOME;

ANIMALS; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRACKING; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JANUS KINASE 2; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STROKE VOLUME; SULFONAMIDES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TYRPHOSTINS; VENTRICULAR FUNCTION, LEFT; Y CHROMOSOME;

EID: 79957682986     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1275     Document Type: Article

References (46)

1. Li RK, Mickle DA, Weisel RD, Rao V, Jia ZQ. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. Ann Thorac Surg 2001; 72: 1957-1963.
2. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: Graft cell death and antideath strategies. J Mol Cell Cardiol 2001; 33: 907-921.
3. Muller-Ehmsen J, Whittaker P, Kloner RA, Dow JS, Sakoda T, Long TI, et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol 2002; 34: 107-116.
4. Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, Dou KF, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 2008; 29: 1578-1590.
5. Yang YJ, Qian HY, Huang J, Li JJ, Gao RL, Dou KF, et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol 2009; 29: 2076-2082.
6. Negoro S, Kunisada K, Tone E, Funamoto M, Oh H, Kishimoto T, et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 2000; 47: 797-805.
7. Omura T, Yoshiyama M, Ishikura F, Kobayashi H, Takeuchi K, Beppu S, et al. Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. J Mol Cell Cardiol 2001; 33: 307-316.
8. Kurdi M, Booz GW. JAK redux: A second look at the regulation and role of JAKs in the heart. Am J Physiol Heart Circ Physiol 2009; 297: H1545-H1556.
9. Dai W, Hale SL, Martin BJ, Kuang JQ, Dow JS, Wold LE, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: Short- and long-term effects. Circulation 2005; 112: 214-223.
10. Muller-Ehmsen J, Peterson KL, Kedes L, Whittaker P, Dow JS, Long TI, et al. Rebuilding a damaged heart: Long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation 2002; 105: 1720-1726.
11. Langeland S, D'Hooge J, Wouters PF, Leather HA, Claus P, Bijnens B, et al. Experimental validation of a new ultrasound method for the simultaneous assessment of radial and longitudinal myocardial deformation independent of insonation angle. Circulation 2005; 112: 2157-2162.
12. Shujia J, Haider HK, Idris NM, Lu G, Ashraf M. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res 2008; 77: 525-533.
13. Niagara MI, Haider H, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007; 100: 545-555.
14. Yasuda T, Weisel RD, Kiani C, Mickle DA, Maganti M, Li RK. Quantitative analysis of survival of transplanted smooth muscle cells with real-time polymerase chain reaction. J Thorac Cardiovasc Surg 2005; 129: 904-911.
15. Lu G, Haider HK, Jiang S, Ashraf M. Sca-1+ stem cell survival and engraftment in the infarcted heart: Dual role for preconditioninginduced connexin-43. Circulation 2009; 119: 2587-2596.
16. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-1201.
17. Li W, Ma N, Ong LL, Nesselmann C, Klopsch C, Ladilov Y, et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007; 25: 2118-2127.
18. Fan L, Lin C, Zhuo S, Chen L, Liu N, Luo Y, et al. Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. Eur J Heart Fail 2009; 11: 1023-1030.
19. Zhang D, Fan GC, Zhou X, Zhao T, Pasha Z, Xu M, et al. Overexpression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol 2008; 44: 281-292.
20. Zhou Q, Liao JK. Statins and cardiovascular diseases: From cholesterol lowering to pleiotropy. Curr Pharm Des 2009; 15: 467-478.
21. Yang YJ, Zhao JL, You SJ, Wu YJ, Jing ZC, Gao RL, et al. Postinfarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel. Eur J Heart Fail 2007; 9: 30-36.
22. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: Multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009; 73: 2110-2117.
23. Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, et al. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in korean patients with untreated intermediate coronary stenosis. Circ J 2011; 75: 398-406.
24. Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, Dou KF, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 2008; 29: 1578-1590.
25. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: From protection to failure. Pharmacol Ther 2008; 120: 172-185.
26. Barry SP, Townsend PA, Latchman DS, Stephanou A. Role of the JAK-STAT pathway in myocardial injury. Trends Mol Med 2007; 13: 82-89.
27. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004; 95: 187-195.
28. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating RISK: A role for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol 2008; 295: H1649-H1656.
29. Levy DE, Darnell JE Jr. Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662.
30. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 2001; 98: 9050-9055.
31. Porter KE, Turner NA. Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255-278.
32. Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: Inhibition by simvastatin. Cardiovasc Res 2004; 64: 507-515.
33. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 2006; 69: 164-177.
34. Howes AL, Arthur JF, Zhang T, Miyamoto S, Adams JW, Dorn GW 2nd, et al. Akt-mediated cardiomyocyte survival pathways are compromised by G alpha q-induced phosphoinositide 4, 5-bisphosphate depletion. J Biol Chem 2003; 278: 40343-40351.
35. Li YJ, Cui W, Tian ZJ, Hao YM, Du J, Liu F, et al. Crosstalk between ERK1/2 and STAT3 in the modulation of cardiomyocyte hypertrophy induced by cardiotrophin-1. Chin Med J (Engl) 2004; 117: 1135-1142.
36. Tian ZJ, Cui W, Li YJ, Hao YM, Du J, Liu F, et al. Different contributions of STAT3, ERK1/2, and PI3-K signaling to cardiomyocyte hypertrophy by cardiotrophin-1. Acta Pharmacol Sin 2004; 25: 1157-1164.
37. Uray KS, Laine GA, Xue H, Allen SJ, Cox CS Jr. Edema-induced intestinal dysfunction is mediated by STAT3 activation. Shock 2007; 28: 239-244.
38. Banes-Berceli AK, Shaw S, Ma G, Brands M, Eaton DC, Stern DM, et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 2006; 291: F116-F121.
39. Mascareno E, El-Shafei M, Maulik N, Sato M, Guo Y, Das DK, et al. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 2001; 104: 325-329.
40. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008; 102: 131-135.
41. Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S, et al. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem 2002; 277: 6676-6681.
42. Stephanou A, Scarabelli TM, Townsend PA, Bell R, Yellon D, Knight RA, et al. The carboxyl-terminal activation domain of the STAT-1 transcription factor enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes. FASEB J 2002; 16: 1841-1843.
43. Stephanou A, Brar BK, Scarabelli TM, Jonassen AK, Yellon DM, Marber MS, et al. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem 2000; 275: 10002-10008.
44. Shen Y, Devgan G, Darnell JE Jr, Bromberg JF. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UVinduced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 2001; 98: 1543-1548.
45. Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is'harc H, et al. Mutational switch of an IL-6 response to an interferongamma- like response. Proc Natl Acad Sci USA 2002; 99: 8043-8047.
46. Qing Y, Stark GR. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 2004; 279: 41679-41685.